Medicines is a biopharmaceutical company. Co. is focused on inclisiran, the investigational RNA interference therapeutic, that inhibits production of proprotein convertase subtilisin/kexin type 9, a main protein that controls low-density lipoprotein-cholesterol levels. Co. has the right to develop, manufacture and commercialize inclisiran under its collaboration agreement with Alnylam Pharmaceuticals, Inc.
|
Free MDCO Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.44 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |